All Content

Trabectedin failed to improve progression-free survival outcomes compared to doxorubicin as first-line therapy for advanced/metastatic soft-tissue sarcoma.

The multi-targeted TKI lenvatinib showed promise in a phase II trial of patients with advanced, radioiodine-refractory, differentiated thyroid cancer.

Metformin, a common drug for type II diabetes, did not improve the survival of patients with pancreatic ductal adenocarcinoma.

This slide show features some of the top highlights from the 2015 American Association for Cancer Research (AACR) Annual Meeting.

A 30-year-old man who recently underwent induction chemotherapy for bone marrow transplant is admitted with neutropenia and right lower-quadrant abdominal pain. What is your diagnosis?

Understanding treatment-induced neurotoxicity can be difficult when treating patients with central nervous system (CNS) malignancies.

A multi-gene panel test provides better diagnostic yield compared with a limited BRCA1/2 genetic test for patients at risk for hereditary breast cancer.

The FDA has approved ramucirumab, a human VEGFR2 antagonist in combination with FOLFIRI for second-line treatment of patients with metastatic colorectal cancer.

Several radiographic texture features from the pre-RT CT scan were identified as potential predictors of pCR in rectal cancer patients after neoadjuvant chemoradiation therapy. Future work will focus on validating these features in a larger dataset.

Patients who undergo surgery after chemoradiotherapy demonstrate improved survival; however, this may be related to underlying comorbidities that preclude surgery. IMRT appears to be a reasonable treatment option that may reduce complications from radiotherapy. Careful attention should be given to heart dose during treatment planning.


By clicking Accept, you agree to become a member of the UBM Medica Community.